| 2023-09-25 | +378.5% | legal | Seeking Alpha | Femasys up 205% as FDA clears fertility treatment |
| 2023-07-27 | +78.3% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2024-02-06 | +50.8% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2023-10-03 | -40.5% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-11-07 | +31.5% | legal | SEC EDGAR | FEMY 8-K: 1.01, 3.02 (SEC Filing) |
| 2025-08-26 | -30.7% | legal | Seeking Alpha | Femasys stock falls after pricing capital raise of $8M via securities offering |
| 2025-10-16 | +27.7% | news | Quiver Quantitative | Femasys Inc. to Showcase Innovative Fertility Solutions at ASRM 2025 Scientific Congress & Expo | FEMY Stock News - Quiver Quantitative |
| 2026-03-27 | -22.5% | news | Stock Titan | Femasys (NASDAQ: FEMY) director receives 102,366 Series D-1 stock warrants - Stock Titan |
| 2026-03-27 | -22.5% | executive | Stock Titan | Femasys (FEMY) CEO receives 68,244 Series D-1 warrants at $0.58 strike - Stock Titan |
| 2026-03-27 | -22.5% | executive | Stock Titan | Femasys (FEMY) CFO receives 34,122 Series D-1 warrants at $0.58 - Stock Titan |
| 2025-11-20 | +21.8% | analyst | Investing.com | Laidlaw initiates Femasys stock with Buy rating on FemaSeed potential - Investing.com |
| 2024-08-09 | +21.6% | earnings | Seeking Alpha | Femasys reports Q2 results |
| 2024-06-20 | +21.1% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-10-17 | -20.9% | legal | SEC EDGAR | FEMY 8-K: 5.02 and (SEC Filing) |
| 2021-06-25 | -19.9% | news | TradingView | Femasys Inc. Income Statement – NASDAQ:FEMY - TradingView |
| 2022-10-06 | +19.4% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-08-11 | -19.1% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.16 |
| 2023-10-11 | -19.1% | news | Seeking Alpha | Femasys regains Nasdaq compliance |
| 2023-10-11 | -19.1% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-05-30 | -19.1% | news | Seeking Alpha | Femasys announces pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5M |
| 2021-06-21 | -19.1% | news | Zacks Investment Research | Should I buy Femasys (FEMY) - Zacks Investment Research |
| 2021-07-20 | +18.6% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-10-06 | +18.6% | news | Benzinga | Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga |
| 2025-05-29 | -17.3% | news | Seeking Alpha | Femasys announces public offering, concurrent private placement |
| 2025-05-29 | -17.3% | news | Intellectia AI | FEMY Forecast — Price Prediction for 2026. Should I Buy FEMY? - Intellectia AI |
| 2024-03-28 | +17.2% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.93, revenue of $1.07M |
| 2024-03-28 | +17.2% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2023-05-12 | -16.5% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.25, revenue of $0.29M |
| 2023-06-08 | -15.9% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2023-05-11 | -15.7% | legal | SEC EDGAR | FEMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-03-13 | -15.7% | legal | SEC EDGAR | FEMY 8-K: 8.01 (SEC Filing) |
| 2024-03-20 | -15.3% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-08-05 | +15.1% | news | Quiver Quantitative | FEMY | Femasys Inc. Common Stock Institutional Ownership - Quiver Quantitative |
| 2023-10-02 | -15.1% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-08-20 | -14.7% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2024-08-08 | -14.2% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2024-05-09 | -13.7% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.17, revenue of $0.27M |
| 2024-05-09 | -13.7% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2025-03-27 | -12.9% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2025-08-08 | -12.7% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2025-08-08 | -12.7% | earnings | Yahoo Finance | Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance |
| 2023-03-30 | -11.6% | legal | SEC EDGAR | FEMY 8-K: 2.02, 5.03 (SEC Filing) |
| 2024-11-12 | -11.3% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.24, revenue of $554.91M |
| 2024-11-12 | -11.3% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2025-11-10 | -11.3% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-11-10 | -11.3% | legal | Stock Titan | Femasys (NASDAQ: FEMY) announces $500K second order for FemBloc in France & Benelux - Stock Titan |
| 2025-12-18 | +11.0% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2026-04-06 | -11.0% | news | Stock Titan | Femasys (NASDAQ: FEMY) targets reverse split and dilutive note, warrant share issuances - Stock Titan |
| 2026-04-06 | -11.0% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is Femasys (FEMY) Stock Good for Portfolio | Price at $0.43, Down 2.16% - Open Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2022-08-10 | -10.7% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2024-08-29 | +10.5% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-06-25 | +10.2% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-06-02 | -10.2% | legal | SEC EDGAR | FEMY 8-K: 1.01, 3.02 (SEC Filing) |
| 2022-01-20 | -10.2% | legal | SEC EDGAR | FEMY 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-01-14 | +9.8% | legal | Seeking Alpha | Femasys secures Nasdaq extension to regain bid price compliance |
| 2026-01-14 | +9.8% | news | Stock Titan | Nasdaq gives Femasys more time to fix sub-$1 share price by July 2026 - Stock Titan |
| 2023-04-18 | -9.8% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2023-04-18 | -9.8% | news | Seeking Alpha | Femasys stock rises on Canada nod for directional insemination product FemaSeed - Seeking Alpha |
| 2026-03-10 | +9.7% | news | GlobeNewswire | Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment |
| 2026-03-10 | +9.7% | news | Stock Titan | Non-surgical permanent birth control FemBloc begins final U.S. trial - Stock Titan |
| 2025-08-06 | -9.7% | legal | Seeking Alpha | Femasys secures first European order for FemBloc |
| 2025-08-06 | -9.7% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-08-06 | -9.7% | legal | Stock Titan | Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion - Stock Titan |
| 2025-12-23 | -9.4% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-05-09 | -9.3% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.23 |
| 2026-03-20 | -8.8% | legal | SEC EDGAR | FEMY 8-K: 1.01, 3.02, 5.02 (SEC Filing) |
| 2024-02-28 | +8.4% | legal | SEC EDGAR | FEMY 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-11-03 | +8.4% | legal | Seeking Alpha | Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges |
| 2025-11-03 | +8.4% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-11-03 | +8.4% | news | Stock Titan | Femasys (NASDAQ: FEMY) to issue $12M notes; warrants lift total potential to $58M - Stock Titan |
| 2025-11-03 | +8.4% | legal | TradingView | Femasys Inc Secures FDA Approval for Final FemBloc Trial Phase - TradingView |
| 2025-11-03 | +8.4% | legal | TipRanks | Femasys Receives FDA Approval for FemBloc Trial - TipRanks |
| 2023-06-26 | -8.4% | legal | Seeking Alpha | Femsys stock jumps 21% after FDA green lights FemBloc testing |
| 2023-06-26 | -8.4% | legal | SEC EDGAR | FEMY 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-06-26 | -8.4% | legal | Stocktwits | Femasys Inc (FEMY) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits |
| 2021-11-12 | -8.2% | news | ChartMill | FEMY Stock Price, Quote & Chart | FEMASYS INC (NASDAQ:FEMY) - ChartMill |
| 2021-11-12 | -8.2% | news | ChartMill | FEMY Technical Analysis | Trend, Signals & Chart Patterns | FEMASYS INC (NASDAQ:FEMY) - ChartMill |
| 2025-05-08 | -7.6% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2022-03-24 | -7.5% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2023-04-20 | -7.5% | legal | SEC EDGAR | FEMY 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2026-03-31 | +7.2% | news | GlobeNewswire | Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update |
| 2026-03-31 | +7.2% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.47, revenue of $2.29M |
| 2026-03-31 | +7.2% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2026-03-31 | +7.2% | news | GlobeNewswire | Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - GlobeNewswire |
| 2026-03-31 | +7.2% | earnings | Stock Titan | Permanent birth control developer starts U.S. trial, cash lasts into Q3 2026 - Stock Titan |
| 2026-03-31 | +7.2% | news | Stock Titan | Femasys (NASDAQ: FEMY) details 2025 results and FemBloc FINALE trial - Stock Titan |
| 2022-08-31 | -7.1% | analyst | TradingView | FEMY Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-03-13 | +6.8% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2021-09-20 | -6.8% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2023-05-04 | -6.6% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2022-10-12 | -6.5% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2023-08-10 | -6.5% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M |
| 2023-08-10 | -6.5% | legal | SEC EDGAR | FEMY 8-K: 2.02, 5.02 (SEC Filing) |
| 2024-03-06 | -6.2% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-11-25 | +6.2% | legal | Stock Titan | PharmaCyte Biotech (Nasdaq: PMCB) Now Holds ~$20M Cash, $25M in Marketable Securities - Stock Titan |
| 2025-11-25 | +6.2% | news | Stocktwits | PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits |
| 2025-11-25 | +6.2% | news | Investing.com | PharmaCyte Biotech stock soars after successful Femasys stake sale - Investing.com |
| 2026-04-13 | +6.1% | news | UBND thành phố Hải Phòng | Is Femasys (FEMY) Stock Breaking Out | Price at $0.40, Up 0.76% - Elite Trading Signals - UBND thành phố Hải Phòng |
| 2026-04-13 | +6.1% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Femasys (FEMY) Stock Breaking Out | Price at $0.40, Up 0.76% - Expert Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2023-11-29 | -6.1% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-07-18 | -6.0% | news | Investing.com | Femasys receives Nasdaq notice for minimum bid price noncompliance - Investing.com |
| 2026-02-03 | +6.0% | news | GlobeNewswire | Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products |
| 2026-02-03 | +6.0% | M&A | Stock Titan | New Swiss deal expands access to permanent birth control and fertility care - Stock Titan |
| 2021-09-01 | -5.9% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2023-11-30 | -5.8% | news | Seeking Alpha | Femasys filed to sell 18.11M shares of common stock for holders |
| 2023-11-30 | -5.8% | executive | Seeking Alpha | Femasys appoints Liu as its chief medical officer |
| 2025-08-27 | -5.6% | legal | SEC EDGAR | FEMY 8-K: 1.01, 3.02 (SEC Filing) |
| 2025-08-27 | -5.6% | news | Yahoo Finance | Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale - Yahoo Finance |
| 2023-11-28 | -5.2% | news | Seeking Alpha | Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner |
| 2023-11-28 | -5.2% | news | Seeking Alpha | Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner - Seeking Alpha |
| 2023-11-14 | -5.0% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.26, revenue of $244.36k |
| 2023-11-14 | -5.0% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2026-04-22 | -4.9% | expansion | GlobeNewswire | Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026 |
| 2026-04-22 | -4.9% | news | Stock Titan | Femasys aims to bring first-line fertility treatment into OB/GYN offices - Stock Titan |
| 2023-10-25 | -4.6% | news | Seeking Alpha | Femasys to showcase FemBloc, other products at medical meeting |
| 2025-04-02 | +4.3% | news | Seeking Alpha | Femasys reports FY results |
| 2023-11-21 | -4.0% | legal | SEC EDGAR | FEMY 8-K: 5.02 (SEC Filing) |
| 2025-01-16 | +3.9% | news | Seeking Alpha | Femasys gets notice of allowance for new U.S. patent application covering use of Femaseed |
| 2022-08-26 | -3.8% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Femasys (FEMY) - Zacks Investment Research |
| 2026-04-01 | +3.7% | executive | GlobeNewswire | Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth |
| 2026-04-01 | +3.7% | executive | Seeking Alpha | Femasys appoints John Canning as COO |
| 2026-04-01 | +3.7% | legal | SEC EDGAR | FEMY 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-04-01 | +3.7% | news | Stock Titan | Medtech veteran joins Femasys to scale fertility, birth control products - Stock Titan |
| 2026-04-01 | +3.7% | executive | Stock Titan | FEMASYS (FEMY) COO awarded 150,000 stock options at $0.38 exercise price - Stock Titan |
| 2026-04-01 | +3.7% | executive | Stock Titan | Femasys (FEMY) COO John Canning discloses ownership of 30,000 shares - Stock Titan |
| 2026-04-01 | +3.7% | executive | Stock Titan | Veteran MedTech leader John Canning joins Femasys (NASDAQ: FEMY) as COO - Stock Titan |
| 2021-09-08 | -3.7% | earnings | Zacks Investment Research | What date does Femasys's (FEMY) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2025-04-24 | -3.6% | news | Stock Titan | FEMY Stock Price, News & Analysis - Stock Titan |
| 2023-04-06 | -3.3% | news | CoinCodex | Femasys Inc. (FEMY) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2022-10-20 | -3.3% | legal | SEC EDGAR | FEMY 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-02-27 | -3.2% | news | GlobeNewswire | Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2022-11-10 | -3.1% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2022-02-24 | -3.1% | legal | SEC EDGAR | FEMY 8-K: 5.02, 8.01 (SEC Filing) |
| 2022-09-29 | -3.0% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2022-05-11 | -2.8% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2025-10-27 | +2.8% | news | TipRanks | Femasys, Inc. Advances Non-Surgical Birth Control with FemBloc Study - TipRanks |
| 2025-11-14 | -2.8% | earnings | Seeking Alpha | Femasys GAAP EPS of -$0.10, revenue of $729M |
| 2025-11-14 | -2.8% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2024-09-11 | +2.8% | expansion | Seeking Alpha | Femasys secures partnerships for commercialization of Femaseed and FemVue |
| 2024-09-11 | +2.8% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2026-04-16 | -2.6% | news | GlobeNewswire | Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio |
| 2026-04-16 | -2.6% | M&A | Stock Titan | Israel fertility clinics get FemaSeed under Femasys-AMI deal - Stock Titan |
| 2021-10-27 | -2.6% | news | Benzinga | Femasys Stock Short Interest Report | NASDAQ:FEMY - Benzinga |
| 2026-04-02 | +2.6% | legal | Stock Titan | FEMY SEC Filings - FEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2023-08-03 | +2.5% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2025-06-17 | -2.4% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2026-03-24 | -2.3% | news | Stock Titan | Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake - Stock Titan |
| 2025-07-03 | -2.2% | legal | SEC EDGAR | FEMY 8-K: 1.01, 3.02 (SEC Filing) |
| 2023-09-27 | +2.1% | legal | SEC EDGAR | FEMY 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-07-01 | -2.1% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2021-07-16 | -2.0% | news | StockInvest.us | Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us |
| 2026-02-26 | +1.9% | news | GlobeNewswire | Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access |
| 2026-02-26 | +1.9% | news | Stock Titan | New non-surgical permanent birth control clears key global quality hurdle - Stock Titan |
| 2025-03-18 | -1.9% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2021-11-10 | -1.9% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |
| 2024-09-09 | -1.6% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2023-06-15 | +1.5% | legal | SEC EDGAR | FEMY 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-03-18 | +1.5% | executive | GlobeNewswire | Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors |
| 2026-03-18 | +1.5% | news | Stock Titan | Stanford-trained anesthesiologist joins Femasys board for women's health - Stock Titan |
| 2026-03-18 | +1.5% | news | Stock Titan | PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan |
| 2023-11-15 | -1.4% | legal | SEC EDGAR | FEMY 8-K: 1.01, 3.01, 3.02, 5.02, 8.01 (SEC Filing) |
| 2025-08-28 | -1.1% | M&A | Stock Titan | Insider Purchase: Femasys CFO Acquires Units; Warrants Exercisable Through 2030 - Stock Titan |
| 2022-12-21 | +0.9% | legal | SEC EDGAR | FEMY 8-K: 8.01 and (SEC Filing) |
| 2023-08-31 | +0.9% | news | Seeking Alpha | Femasys obtains license to sell its products in Canada |
| 2026-02-23 | +0.9% | news | GlobeNewswire | Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination |
| 2025-01-30 | +0.9% | news | Seeking Alpha | Femasys announces notices of intention to grant for two new European patent applications |
| 2026-03-06 | -0.7% | earnings | ChartMill | FEMY Earnings History & Surprises | EPS & Revenue Results | FEMASYS INC (NASDAQ:FEMY) - ChartMill |
| 2021-09-09 | +0.4% | news | TradingView | FEMY Stock Price and Chart — NASDAQ:FEMY - TradingView |
| 2026-04-18 | +0.2% | M&A | UBND thành phố Hải Phòng | Femasys (FEMY) Stock Jumps on Deal (+0.71%) 2026-04-18 - Community Watchlist - UBND thành phố Hải Phòng |
| 2021-08-11 | +0.2% | legal | SEC EDGAR | FEMY 8-K: 2.02 and (SEC Filing) |